About: Low testosterone levels predict clinical adverse outcomes in SARS‐CoV‐2 pneumonia patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Low testosterone levels predict clinical adverse outcomes in SARS‐CoV‐2 pneumonia patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Low testosterone levels predict clinical adverse outcomes in SARS‐CoV‐2 pneumonia patients
Creator	Cervi, Giulia Cipriani, Sarah Corona, Giovanni De Donno, Giuseppe Greco, Francesca Inglese, Francesco Lenzi, Andrea Linda Vignozzi, \| Maggi, Mario Magini, Angela Maseroli, Elisa Massimiliano Beccaria, \| Pecoriello, Antonietta Rastrelli, Giulia Salonia, Andrea Stasi, Vincenza Todisco, Tommaso
source	Medline; PMC
abstract	BACKGROUND: The pandemic of new severe acute respiratory syndrome (SARS) due to coronavirus (CoV) 2 (SARS‐CoV‐2) has stressed the importance of effective diagnostic and prognostic biomarkers of clinical worsening and mortality. Epidemiological data showing a differential impact of SARS‐CoV‐2 infection on women and men have suggested a potential role for testosterone (T) in determining gender disparity in the SARS‐CoV‐2 clinical outcomes. OBJECTIVES: To estimate the association between T level and SARS‐CoV‐2 clinical outcomes (defined as conditions requiring transfer to higher or lower intensity of care or death) in a cohort of patients admitted in the respiratory intensive care unit (RICU). MATERIALS AND METHODS: A consecutive series of 31 male patients affected by SARS‐CoV‐2 pneumonia and recovered in the respiratory intensive care unit (RICU) of the “Carlo Poma” Hospital in Mantua were analyzed. Several biochemical risk factors (ie, blood count and leukocyte formula, C‐reactive protein (CRP), procalcitonin (PCT), lactate dehydrogenase (LDH), ferritin, D‐dimer, fibrinogen, interleukin 6 (IL‐6)) as well as total testosterone (TT), calculated free T (cFT), sex hormone–binding globulin (SHBG), and luteinizing hormone (LH) were determined. RESULTS: Lower TT and cFT were found in the transferred to ICU/deceased in RICU group vs groups of patients transferred to IM or maintained in the RICU in stable condition. Both TT and cFT showed a negative significant correlation with biochemical risk factors (ie, the neutrophil count, LDH, and PCT) but a positive association with the lymphocyte count. Likewise, TT was also negatively associated with CRP and ferritin levels. A steep increase in both ICU transfer and mortality risk was observed in men with TT < 5 nmol/L or cFT < 100 pmol/L. DISCUSSION AND CONCLUSION: Our study demonstrates for the first time that lower baseline levels of TT and cFT levels predict poor prognosis and mortality in SARS‐CoV‐2‐infected men admitted to RICU.
has issue date	2020-06-03(xsd:dateTime)
bibo:doi	10.1111/andr.12821
bibo:pmid	32436355
has license	no-cc
sha1sum (hex)	82a44217b10d03f0a13031dacfc1e48b68f42714
schema:url	https://doi.org/10.1111/andr.12821
resource representing a document's title	Low testosterone levels predict clinical adverse outcomes in SARS‐CoV‐2 pneumonia patients
has PubMed Central identifier	PMC7280645
has PubMed identifier	32436355
schema:publication	Andrology
resource representing a document's body	covid:82a44217b10d03f0a13031dacfc1e48b68f42714#body_text
is schema:about of	named entity 'data' named entity 'biomarkers' named entity 'Epidemiological' named entity 'testosterone' named entity 'patients' named entity 'DUE TO' named entity 'PATIENTS' named entity 'differential' named entity 'men' named entity 'prognostic' named entity 'pneumonia' named entity 'Epidemiological data' named entity 'severe acute respiratory syndrome' named entity 'infection' named entity 'SARS' named entity 'gender disparity' named entity 'prognosis' named entity 'transcription' named entity 'diabetes mellitus' named entity 'PaO2/FiO2' named entity 'clinical outcomes' named entity 'testosterone' named entity 'ARDS' named entity 'Kruskal-Wallis test' named entity 'SARS-CoV-2' named entity 'natural killer (NK) cells' named entity 'ARDS' named entity 'SARS-CoV-2' named entity 'LDH' named entity 'testosterone' named entity 'angiotensin II' named entity 'respiratory conditions' named entity 'discrimination' named entity 'testosterone' named entity 'immunoassay' named entity 'CPK' named entity 'testosterone' named entity 'CD4' named entity 'infection' named entity 'D-dimer' named entity 'biochemical' named entity 'blood count' named entity 'ARDS' named entity 'lymphocyte count' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'non-linear change' named entity 'testosterone' named entity 'severe respiratory failure' named entity 'intensive care unit' named entity 'ACE2' named entity 'testosterone' named entity 'cytokine storm' named entity 'Italy' named entity 'diagnostic workup' named entity 'SARS-CoV-2' named entity 'fibrinogen' named entity 'neutrophil' named entity 'epidemiological' named entity 'physiology' named entity 'Berlin' named entity 'luteinizing hormone' named entity 'Mantua' named entity 'control group'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software